Sagimet Biosciences
San Mateo
About Sagimet Biosciences
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $406.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2024)
- Ticker: nasdaq:SGMT
- Website: sagimet.com
- Phone: +1 650.561.8600
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sagimet-biosciences-24928 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.